Ozempic for weight loss is disrupting companies’ business model
Leslie Patton | (TNS) Bloomberg News As sales of appetite-suppressing drugs such as Ozempic and Mounjaro skyrocket, corporate America is grappling with the question: How does a less-hungry, less-impulse-prone consumer affect my business model? Companies from Walmart Inc. to Conagra Brands Inc. are weighing how much to factor the diabetes drugs known as GLP-1s, increasingly…
Read more